UBS Group AG Has $7.85 Million Stake in Soleno Therapeutics, Inc. $SLNO

UBS Group AG increased its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 7.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 169,506 shares of the company’s stock after buying an additional 11,198 shares during the period. UBS Group AG owned 0.32% of Soleno Therapeutics worth $7,848,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Soleno Therapeutics by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock worth $141,695,000 after purchasing an additional 253,212 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Soleno Therapeutics by 25.7% in the third quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock valued at $174,258,000 after buying an additional 527,777 shares during the period. Wellington Management Group LLP increased its holdings in Soleno Therapeutics by 272.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock worth $156,298,000 after purchasing an additional 1,691,057 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Soleno Therapeutics by 132.3% in the third quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock valued at $101,435,000 after purchasing an additional 854,551 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Soleno Therapeutics by 20.2% during the second quarter. State Street Corp now owns 1,404,983 shares of the company’s stock worth $117,709,000 after buying an additional 235,784 shares during the period. 97.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on SLNO shares. Oppenheimer dropped their target price on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 18th. Lifesci Capital cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Cantor Fitzgerald downgraded shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the company from $123.00 to $53.00 in a report on Monday, April 6th. Wolfe Research lowered shares of Soleno Therapeutics from an “outperform” rating to a “hold” rating in a research report on Tuesday, April 7th. Finally, Robert W. Baird cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $76.67.

Soleno Therapeutics Stock Up 0.0%

NASDAQ:SLNO opened at $53.01 on Tuesday. Soleno Therapeutics, Inc. has a twelve month low of $29.43 and a twelve month high of $90.32. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 29.95 and a beta of -2.22. The company has a quick ratio of 5.32, a current ratio of 5.62 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average price is $45.26 and its two-hundred day moving average price is $45.70.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Soleno Therapeutics had a return on equity of 22.85% and a net margin of 33.70%. Equities research analysts expect that Soleno Therapeutics, Inc. will post 3.67 earnings per share for the current fiscal year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.